RA
PDLI

Royce & Associates’s PDL BioPharma, Inc. PDLI Stock Holding History

Royce & Associates’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,036
Closed -$19K – 1262
2018
Q2 		$19K Buy
8,036
+3,414
+74% +$9.53K ﹤0.01% 1137
2018
Q1 		$14K Sell
4,622
-393
-8% -$1.07K ﹤0.01% 1134
2017
Q4 		$14K Buy
5,015
+713
+17% +$2.19K ﹤0.01% 1134
2017
Q3 		$15K Buy
+4,302
New +$12K ﹤0.01% 1114

Other funds holding PDLI

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Royce & Associates's PDLI Position: Q3 2018 in Review

Royce & Associates sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 8,036 shares — an estimated $19K sold.

Royce & Associates first reported a position in PDLI in Q3 2017 and held it in 4 quarters. The position peaked at $19K in Q2 2018. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

  • Royce & Associates reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
  • Royce & Associates sold 8,036 PDL BioPharma, Inc. shares in Q3 2018, an estimated $19K.
  • Royce & Associates first reported a position in PDL BioPharma, Inc. in Q3 2017 and held it in 4 quarters.
  • Royce & Associates's PDL BioPharma, Inc. position peaked at $19K in Q2 2018.
  • 152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on Royce & Associates's 13F filing for Q3 2018, filed 13 Nov 2018.